NBSE's logo.
Ticker Symbol: NBSE

NeuBase Therapeutics Inc

$3.49 - 20-12-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0001173281

Company Profile

NeuBase Therapeutics Inc. is accelerating the genetic revolution using a new class of synthetic medicines which have been shown to be able to increase, decrease and change gene function, as appropriate, to resolve causal genetic defects in living systems. NeuBase's designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 700 Technology Dr
CEO: Dietrich Stephan
Tags:
  • Health Technology
  • Biotechnology
  • Pharmaceuticals: Major
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $0.75
Change: -$0.05 ( -7.05%)
Days Range: $0.73 - $0.81
Beta: 1.70
52wk. High: $8.19
52wk. Low: $0.60
Ytd. Change -85.78%
50 Day Moving Average: $1.02
200 Day Moving Average: $2.09
Shares Outstanding: 2362377

Valuation

Market Cap: 177.7M
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A